Gregory A. Curt
- Oncology top 1%
- Cancer Treatment and Pharmacology 8
- Cancer survivorship and care 8
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments 6
-
- Childhood Cancer Survivors' Quality of Life 5
-
- Lung Cancer Treatments and Mutations 6
-
- Cancer therapeutics and mechanisms 6
-
- Acute Lymphoblastic Leukemia research 6
-
- HIV/AIDS drug development and treatment 4
- Co-authors
- David CellaWilliam BreitbartBruce A. ChabnerJacques JolivetNeil J. ClendeninnSandra J. HorningJerome E. GroopmanRussell K. Portenoy
- Journals
- The Oncologist (10 papers)Journal of Clinical Oncology (7 papers)Investigational New Drugs (4 papers)
- Partner nations
- United StatesUnited KingdomMalaysia
In The Last Decade
Gregory A. Curt
60 papers receiving 5.0k citations
Hit Papers
Peers
Comparison fields: 5 of 143
- Oncology 2.5k
- Hematology 744
- Pediatrics, Perinatology and Child Health 1.2k
- Complementary and alternative medicine 304
- Pulmonary and Respiratory Medicine 1.0k
Countries citing papers authored by Gregory A. Curt
This map shows the geographic impact of Gregory A. Curt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Curt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Curt more than expected).
Fields of papers citing papers by Gregory A. Curt
This network shows the impact of papers produced by Gregory A. Curt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Curt. The network helps show where Gregory A. Curt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gregory A. Curt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 15 | |
| 2 | 2017 | 13 | |
| 3 | 2011 | 36 | |
| 4 | Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. - eScholarship | 2011 | 1 |
| 5 | 2002 | 95 | |
| 6 | 2001 | 2 | |
| 7 | 2001 | 487 | |
| 8 | 2000 | 203 | |
| 9 | 2000 | 139 | |
| 10 | 2000 | 122 | |
| 11 | 1997 | 148 | |
| 12 | 1996 | 28 | |
| 13 | 1993 | 134 | |
| 14 | 1990 | 20 | |
| 15 | 1990 | 4 | |
| 16 | 1990 | 9 | |
| 17 | 1985 | 7 | |
| 18 | 1984 | 11 | |
| 19 | 1982 | 5 | |
| 20 | 1979 | 2 |
About Gregory A. Curt
Gregory A. Curt is a scholar working on Hematology, Oncology and Genetics, having authored 62 papers that have together received 5.3k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Cancer survivorship and care (8 papers), Cancer therapeutics and mechanisms (6 papers), Lung Cancer Treatments and Mutations (6 papers), Chronic Myeloid Leukemia Treatments (6 papers), Acute Lymphoblastic Leukemia research (6 papers), Childhood Cancer Survivors' Quality of Life (5 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Oncology (2.5k citations), Hematology (744 citations) and Pediatrics, Perinatology and Child Health (1.2k citations). Gregory A. Curt has collaborated with scholars based in United States, United Kingdom and Malaysia. Frequent co-authors include David Cella, William Breitbart, Bruce A. Chabner, Jacques Jolivet, Neil J. Clendeninn, Sandra J. Horning, Jerome E. Groopman, Russell K. Portenoy, Nicholas J. Vogelzang and Loretta M. Itri. Their work appears in journals such as The Oncologist, Journal of Clinical Oncology, Investigational New Drugs, Cancer and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.